180 Life Sciences Corp. - ATNF STOCK NEWS

180 Life Sciences Corp. (NASDAQ: ATNF) has received written feedback from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and the U.S. FDA regarding its anti-TNF treatment for early-stage Dupuytren’s disease. The MHRA has advised that no further non-clinical studies are needed, but requires evidence validating clinical endpoints. The FDA criticized the proposed outcome measures as inadequate for efficacy demonstration and suggested a pre-investigational new drug meeting for more guidance. Approximately 12 million people in the U.S. suffer from this degenerative condition.

180 Life Sciences Corp. (NASDAQ: ATNF) announced the initiation of consultations with regulatory agencies in the UK and USA regarding their Phase 2b trial for Dupuytren’s disease treatment. Positive data from the trial, published in The Lancet Rheumatology, suggests a potential for earlier intervention in patients with this progressive condition. The FDA will respond to the company’s briefing materials, shaping future development strategies. Currently, no approved treatments exist for early-stage Dupuytren’s disease, indicating a significant market opportunity for the company.

180 Life Sciences Corp. (NASDAQ: ATNF) announced positive results from its Phase 2b trial for Dupuytren's disease, published in The Lancet Rheumatology. The study achieved its primary endpoint, showing a significant reduction in nodule hardness at 12 months and continued improvement at 18 months post-treatment. Key findings include a decrease in nodule size and high patient compliance (84%). The trial, funded by the Health Innovation Challenge Fund and 180 Life Sciences, suggests that anti-TNF treatment could offer an effective early intervention option for this debilitating condition.

180 Life Sciences Corp. (NASDAQ: ATNF) announced positive final results from its Phase 2b study of anti-TNF treatment for Dupuytren's disease, published in The Lancet Rheumatology. The study achieved its primary endpoint of reduced nodule hardness at 12 months and demonstrated ongoing improvement at 18 months, suggesting durable benefits from treatment. The trial showed a decrease in nodule size and high patient compliance, with no serious adverse events reported. This study supports anti-TNF therapy as a promising early treatment option for Dupuytren's disease, which currently lacks approved therapies.

180 Life Sciences Corp. (NASDAQ: ATNF) has formed a scientific advisory board (SAB) to enhance its clinical development capabilities. The board includes notable experts such as Dr. Raphael Mechoulam and Dr. Kevin Tracey, who will guide the company's focus on inflammatory diseases and pain management. Following recent positive Phase 2b results in Dupuytren’s Contracture, 180 Life Sciences is set to discuss regulatory pathways with the FDA and MHRA. This strategic move aims to strengthen its pipeline and expedite commercialization efforts.

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology firm, addressed shareholders in a letter from CEO Dr. James Woody, acknowledging recent market declines impacting stock prices. The letter highlighted continued confidence in the company's fundamentals following positive Phase 2b trial results for Dupuytren’s Contracture, with anticipated publication in a peer-reviewed journal. The company, targeting a significant market opportunity estimated at $800M, is pursuing regulatory approvals and exploring strategic partnerships. Financial discipline is emphasized to navigate macroeconomic headwinds.

180 Life Sciences Corp. (NASDAQ: ATNF) announced its participation in the Biotech Showcase 2022 Virtual Conference from January 10-12, 2022. Dr. James Woody, the Company's CEO, will present an overview of its business and is available for virtual meetings. The conference focuses on innovations in the life sciences industry, covering recent opportunities and challenges. 180 Life Sciences is dedicated to developing novel drugs for inflammatory diseases, fibrosis, and pain, leveraging expertise from notable institutions like Oxford and Stanford.

180 Life Sciences (NASDAQ: ATNF) has announced a global licensing agreement with The University of Oxford for the development of HMGB1, a regenerative molecule aimed at promoting liver repair. The agreement involves a small upfront fee with additional payments contingent on clinical milestones. This initiative targets liver disorders such as NASH, a condition with no approved therapies. The collaboration aims to advance GMP production and safety testing in preparation for an Investigational New Drug application.

180 Life Sciences Corp. (NASDAQ: ATNF) announced positive top-line results from its Phase 2b clinical trial for Dupuytren’s disease, demonstrating significant reductions in nodule hardness and size. The trial met both primary and secondary endpoints, showing high patient compliance without serious adverse events. Although detailed data cannot be released due to publication policies, the Company anticipates commercialization discussions with regulatory bodies in 2022. 180 Life Sciences aims to lead in fibrosis therapies, with no current competitors for early-stage Dupuytren’s disease treatments.